NASDAQ:KTTA Pasithea Therapeutics (KTTA) Stock Price, News & Analysis $0.49 -0.01 (-1.52%) Closing price 04:00 PM EasternExtended Trading$0.49 0.00 (-0.28%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Pasithea Therapeutics Stock (NASDAQ:KTTA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pasithea Therapeutics alerts:Sign Up Key Stats Today's Range$0.48▼$0.5150-Day Range$0.49▼$0.8552-Week Range$0.28▼$2.06Volume182,116 shsAverage Volume1.63 million shsMarket Capitalization$12.28 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingHold Company Overview Pasithea Therapeutics, Inc. (NASDAQ: KTTA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and eventual commercialization of engineered antibody therapeutics for immunological diseases. Leveraging a proprietary discovery engine that integrates advanced computational biology, high-throughput screening and structural analysis, the company aims to identify and generate novel therapeutic molecules that modulate key immune pathways. The company’s pipeline consists of multiple preclinical and early clinical candidates targeting autoimmune and inflammatory disorders. Pasithea’s research approach centers on human-derived antibodies with tailored specificity and functionality, addressing areas of high unmet need such as severe chronic inflammatory conditions. By applying its platform to a range of targets, Pasithea seeks to advance innovative therapies toward regulatory milestones and strategic partnerships. Headquartered in Seattle, Washington, Pasithea Therapeutics maintains research and development operations in the Pacific Northwest, with teams dedicated to antibody engineering, translational science and regulatory strategy. The company is led by a management team with experience in biotechnology innovation, clinical development and commercialization, supported by a board of directors and scientific advisors drawn from leading academic and industry institutions. Pasithea continues to explore collaborations with academic centers and pharmaceutical partners to accelerate its therapeutic programs.AI Generated. May Contain Errors. Read More Pasithea Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreKTTA MarketRank™: Pasithea Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 510th out of 849 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingPasithea Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialPasithea Therapeutics has a consensus price target of $3.00, representing about 509.3% upside from its current price of $0.49.Amount of Analyst CoveragePasithea Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Pasithea Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Pasithea Therapeutics are expected to decrease in the coming year, from ($0.76) to ($1.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pasithea Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pasithea Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPasithea Therapeutics has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Pasithea Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.18% of the float of Pasithea Therapeutics has been sold short.Short Interest Ratio / Days to CoverPasithea Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pasithea Therapeutics has recently decreased by 7.83%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPasithea Therapeutics does not currently pay a dividend.Dividend GrowthPasithea Therapeutics does not have a long track record of dividend growth. News and Social Media1.3 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for Pasithea Therapeutics this week, compared to 2 articles on an average week.Search Interest2 people have searched for KTTA on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Pasithea Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pasithea Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders2.00% of the stock of Pasithea Therapeutics is held by insiders.Percentage Held by Institutions23.92% of the stock of Pasithea Therapeutics is held by institutions.Read more about Pasithea Therapeutics' insider trading history. Receive KTTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KTTA Stock News HeadlinesPasithea Therapeutics (NASDAQ:KTTA) Trading Down 1.6% - Here's What HappenedJuly 9 at 2:43 AM | americanbankingnews.comPasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision SummitJuly 8 at 7:02 AM | globenewswire.comTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.July 10 at 1:00 AM | Reagan Gold Group (Ad)Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF ...June 30, 2026 | finance.yahoo.comPasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol ExpansionJune 30, 2026 | globenewswire.comPasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical TrialJune 16, 2026 | globenewswire.comPasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF ConferenceJune 15, 2026 | finance.yahoo.comPasithea Therapeutics to Engage with NF1 Community at 2026 Children's Tumor Foundation Conference Following FDA Designations for PAS-004June 15, 2026 | quiverquant.comQSee More Headlines KTTA Stock Analysis - Frequently Asked Questions How have KTTA shares performed this year? Pasithea Therapeutics' stock was trading at $1.29 at the start of the year. Since then, KTTA stock has decreased by 61.8% and is now trading at $0.4924. How were Pasithea Therapeutics' earnings last quarter? Pasithea Therapeutics Corp. (NASDAQ:KTTA) posted its quarterly earnings results on Friday, May, 15th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.33. When did Pasithea Therapeutics' stock split? Pasithea Therapeutics's stock reverse split before market open on Tuesday, January 2nd 2024.The 1-20 reverse split was announced on Tuesday, January 2nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Pasithea Therapeutics IPO? Pasithea Therapeutics (KTTA) raised $17 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 2,898,551 shares at $5.00-$7.00 per share. How do I buy shares of Pasithea Therapeutics? Shares of KTTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pasithea Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pasithea Therapeutics investors own include Biofrontera (BFRI), Meta Platforms (META), Plug Power (PLUG), QuantumScape (QS), Airbnb (ABNB), Advanced Micro Devices (AMD) and Ginkgo Bioworks (DNA). Company Calendar Last Earnings5/15/2026Today7/10/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 KTTA's financial health is in the Yellow zone, according to TradeSmith. KTTA has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KTTA CIK1841330 Webwww.pasithea.com Phone702-514-4174FaxN/AEmployees3Year Founded2020Price Target and Rating Average Price Target for Pasithea Therapeutics$3.00 High Price Target$3.00 Low Price Target$3.00 Potential Upside/Downside+509.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($2.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.43 million Net MarginsN/A Pretax MarginN/A Return on Equity-57.44% Return on Assets-53.61% Debt Debt-to-Equity RatioN/A Current Ratio35.41 Quick Ratio35.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.39 per share Price / Book0.21Miscellaneous Outstanding Shares24,940,000Free Float24,441,000Market Cap$12.28 million OptionableNot Optionable Beta0.29 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free Report This page (NASDAQ:KTTA) was last updated on 7/10/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredIs the fix for AI's runaway power problem your golden ticket?The government just committed $200 billion to building computer chips on American soil - one of the largest te...Eagle Publishing | SponsoredRay Dalio: Buy Gold. Get Paid.Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...Investors Alley | SponsoredBofA: Digital Dollar Coming 2025-2030Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredA better retirement stock than Berkshire?Whitney Tilson - the analyst CNBC called 'The Prophet' for early calls on Netflix, Apple, and Amazon - says he...Stansberry Research | SponsoredExecutive order could send gold to 6,000 per ounceExecutive Order 14330 will allow Americans to hold precious metals inside 401(k)s for the first time ever - an...Cedar Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
